First Tracks Biotherapeutics (NASDAQ:TRAX) Upgraded at Wells Fargo & Company

First Tracks Biotherapeutics (NASDAQ:TRAX) was upgraded by investment analysts at Wells Fargo & Company to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research analysts have also issued reports on the company. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. Piper Sandler started coverage on First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 target price on the stock. UBS Group started coverage on First Tracks Biotherapeutics in a research note on Tuesday, April 21st. They set a “buy” rating and a $45.00 price target on the stock. Barclays started coverage on First Tracks Biotherapeutics in a research note on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, First Tracks Biotherapeutics currently has an average rating of “Buy” and an average price target of $38.25.

First Tracks Biotherapeutics Trading Down 5.1%

TRAX opened at $15.75 on Monday. First Tracks Biotherapeutics has a 12 month low of $14.72 and a 12 month high of $26.80.